Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Clinical Possibility of Caenorhabditis elegans as a Novel Evaluation Tool for Esophageal Cancer Patients Receiving Chemotherapy: A Prospective Study

Yuta Sato
,
Manabu Futamura
* ORCID logo ,
Yoshihiro Tanaka
,
Hiroshi Tsuchiya
,
Masahiro Fukada
ORCID logo ,
Toshiya Higashi
,
Itaru Yasufuku
,
Ryuichi Asai
,
Jesse Yu Tajima
,
Shigeru Kiyama
,
Hideyuki Hatakeyama
,
Masayo Morishita
,
Takaaki Hirotsu
,
Eric di Luccio
ORCID logo ,
Takuma Ishihara
ORCID logo ,
Nobuhisa Matsuhashi
,
Kazuhiro Yoshida
Version 1 : Received: 29 June 2023 / Approved: 30 June 2023 / Online: 3 July 2023 (09:31:24 CEST)

A peer-reviewed article of this Preprint also exists.

Sato, Y.; Futamura, M.; Tanaka, Y.; Tsuchiya, H.; Fukada, M.; Higashi, T.; Yasufuku, I.; Asai, R.; Tajima, J.Y.; Kiyama, S.; Hatakeyama, H.; Morishita, M.; Hirotsu, T.; Luccio, E.D.; Ishihara, T.; Matsuhashi, N.; Yoshida, K. Clinical Possibility of Caenorhabditis elegans as a Novel Evaluation Tool for Esophageal Cancer Patients Receiving Chemotherapy: A Prospective Study. Cancers 2023, 15, 3870. Sato, Y.; Futamura, M.; Tanaka, Y.; Tsuchiya, H.; Fukada, M.; Higashi, T.; Yasufuku, I.; Asai, R.; Tajima, J.Y.; Kiyama, S.; Hatakeyama, H.; Morishita, M.; Hirotsu, T.; Luccio, E.D.; Ishihara, T.; Matsuhashi, N.; Yoshida, K. Clinical Possibility of Caenorhabditis elegans as a Novel Evaluation Tool for Esophageal Cancer Patients Receiving Chemotherapy: A Prospective Study. Cancers 2023, 15, 3870.

Abstract

Background The nematode Caenorhabditis elegans (C. elegans) possesses a sophisticated sense of smell and is used for a novel cancer screening test that utilizes the chemotaxis index. We designed a single-institution, prospective study to confirm the ability of Nematode Nose (N-NOSE) to determine preoperative chemotherapy's efficacy for esophageal cancer patients. Patients and Methods We investigated the predictability of N-NOSE screening for the clinical effects of preoperative chemotherapy for esophageal cancer patients receiving radical surgery. The index reduction score (IRS) was calculated by chemotaxis of C. elegans at three points: before treatment, before surgery, and after surgery, and its clinical relevance was examined. Result Thirty-nine patients with esophageal cancer were enrolled from August 2020 to December 2021 and 30 patients receiving radical surgery were examined. Complete response or partial response was achieved in 23 cases (76.7%). When the target of the treatment effect was complete response only, the prediction accuracies of the IRS calculated by area under the curve was 0.85 (95% Confidence interval: 0.62-1) in clinically achieving complete response group, and the sensitivity and specificity were 1 and 0.63, respectively. Conclusion Index reduction score using N-NOSE screening may reflect the efficacy of chemotherapy for esophageal cancer patients. A large-scale prospective study at multiple centers is desired in the future.

Keywords

Esophageal cancer; Caenorhabditis elegans; N-NOSE; Preoperative chemotherapy

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.